Wall Street swoons over Amgen's D-mab future

It's been a long time since I've heard the words "love" and "Amgen" in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's performance in a recent clinical trial. Oppenheimer's Bret Holley says the drug is on track to break the billion-dollar mark in 2010 with an approval possible in 2009. And that helped send shares of Amgen surging to a 14-month high.

- reaad the story from the Los Angeles Times

Related Articles:
Denosumab--Next gen biotech blockbusters
Amgen shares buoyed by late-stage D-mab data
Amgen's D-mab posts positive in late-stage trial
Amgen's D-mab meets trial goal
Denosumab: Amgen's salvation?